Our findings supported our hypothesis, we discovered a notable association between elevated expression levels of RBFOX2 and decreased response to treatment, along with unfavorable progression-free survival (PFS) outcomes in patients with advanced NSCLC and melanoma who received immunotherapy (Figures 6A,B,D,E). Here, RBFOX2 is linked to non-small cell lung carcinoma.